Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.

Differences between treatment groups did not reach statistical significance for the three subsequent secondary efficacy end points of NRM by day +180 (10 patients (6.0%) in the vedolizumab group and 19 (11.5%) in the placebo group), overall survival by day +180 (89.7% versus 84.4%, respectively) and IBMTR grade B–D aGVHD of any organ-free survival by day +180 (66.4% versus 52.3%, respectively).

also in 111,027 other papers